Acute amivantamab-induced myocardial injury in a patient with epidermal growth factor receptor-mutant lung cancer: a first case report
When treating patients with amivantamab, oncologists should screen for cardiac disease-related symptoms, even in the absence of elevated cardiac serum biomarkers. Furthermore, when amivantamab-induced myocardial injury is suspected, a cardiologist should be consulted promptly, as the dysfunction may be reversible.
Authors
- Noritaka Honda
- Mayako Mori
- Kazumasa Akagi (ORCID: https://orcid.org/0000-0002-5487-0453)
- Tsuyoshi Yoshimuta (ORCID: https://orcid.org/0000-0003-4694-5547)
- Hiroshi Mukae (ORCID: https://orcid.org/0000-0002-1429-5706)
- Hiromi Tomono (ORCID: https://orcid.org/0009-0006-2748-9418)
- Shinnosuke Takemoto (ORCID: https://orcid.org/0000-0003-0373-0618)
- Toru Morikawa (ORCID: https://orcid.org/0000-0001-8014-5282)
- Midori Matsuo
- Tetsufumi Motokawa
- Tomoaki Inoue (ORCID: https://orcid.org/0000-0002-9693-5040)
- Seiya Kaneko
- Hirokazu Taniguchi (ORCID: https://orcid.org/0000-0002-1571-9558)
- Yosuke Dotsu
Institutions
- University of Nagasaki (JP)
- Inoue Hospital (JP)
- Nagasaki University Hospital (JP)
- Nagasaki University (JP)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.3389/fonc.2025.1708575
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 1.39